
Retrogenix appoints US director
pharmafile | June 26, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | britz, retrogenix
Biotech firm Retrogenix has appointed Matthew Britz as its North American business development director.
Britz will operate out of the firm’s US offices in Cambridge, MA, and play a role in supporting the company’s expansion plans in the US and Canadian markets. The firm also has a UK office in Manchester.
Britz recently held business development and strategy consultancy roles within life sciences companies, and has experience in both scientific and managerial positions within several global pharma firms.
Dr Jim Freeth the managing director of Retrogenix, says: “Matt will be an excellent ambassador for Retrogenix, he has first-hand experience of the challenges that our clients face in drug discovery and development, making him an incredibly valuable asset. We look forward to supporting him in this new role.”
Britz adds: “I am delighted to be part of a team that is having such a major positive impact on the industry and facilitating breakthroughs in medical research through its partnerships with leading academics.”






